Zhejiang Cancer Hospital
🇨🇳China
Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen
Phase 2
- Conditions
- Advanced Biliary Tract Tumors
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04191343
- Locations
- 🇨🇳
Haijun Zhong, Zhenjiang, Hangzhou, China
Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study
Phase 2
- Conditions
- Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 116
- Registration Number
- NCT04190745
- Locations
- 🇨🇳
Jieer Ying, Hangzhou, Zhejiang, China
Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC
Phase 2
- Conditions
- Small Cell Lung Cancer Limited Stage
- Interventions
- First Posted Date
- 2019-12-06
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT04189094
Single Cell Sequencing Analysis of Thymoma
Recruiting
- Conditions
- Thymoma
- Interventions
- Diagnostic Test: Tissue
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT04162691
- Locations
- 🇨🇳
An Zhao, Hangzhou, China
Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC
- Conditions
- Unresectable Stage III NSCLC
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2019-11-13
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT04161352
Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer
Phase 3
Recruiting
- Conditions
- Stomach Cancer
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 616
- Registration Number
- NCT04135781
- Locations
- 🇨🇳
Zhejiang Cancer Hospital；Cancer hospital of the university of chinese academy of sciences, Hangzhou, Zhejiang, China
CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical Cancer
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT04121975
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma
Phase 1
Completed
- Conditions
- Glioblastoma
- Interventions
- Drug: Drug is Anlotinib.Drug: Drug is Temozolomide Capsule.Radiation: Radiotherapy was initiated 4 to 6 weeks postoperatively.
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 33
- Registration Number
- NCT04119674
- Locations
- 🇨🇳
Zhejiang cancer hospital, Hangzhou, Zhejiang, China
A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
Phase 2
Suspended
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: Paclitaxel, Albumin-BoundRadiation: RadiotherapyDrug: Platinum-Based Drug
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04084158
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04066543
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
© Copyright 2025. All Rights Reserved by MedPath